Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) GF Value : $0.00 (As of May. 06, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Omni Bio Pharmaceutical GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-06), Omni Bio Pharmaceutical's share price is $0.001. Omni Bio Pharmaceutical's GF Value is $0.00. Therefore, Omni Bio Pharmaceutical's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Omni Bio Pharmaceutical is Not Valued.

Omni Bio Pharmaceutical (GREY:OMBP) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Omni Bio Pharmaceutical's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.001	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omni Bio Pharmaceutical GF Value Related Terms

Thank you for viewing the detailed overview of Omni Bio Pharmaceutical's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omni Bio Pharmaceutical Inc (GREY:OMBP) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

5350 South Roslyn, Suite 430, Greenwood Village, CO, USA, 80111

Website

http://www.omnibiopharma.com

Omni Bio Pharmaceutical Inc is a US-based biopharmaceutical company, which is engaged in the exploration of new methods of use of alpha-1 antitrypsin (AAT). It offers AAT, a naturally occurring protein that is essential for normal liver and lung function and has been purified from human blood to treat patients suffering from emphysema due to AAT-deficiency. Further, it focuses on the research and development efforts of advancing its first recombinant molecule, AAT and an Fc component of immunoglobulin (AAT-Fc 2) into clinical trials. Geographically these activities are functioned through the region of US.

Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Headlines

No Headlines